The document lists the products authorized in Canada by class, including Ozempic and Rybelsus (semaglutide), Victoza (liraglutide), Trulicity (dulaglutide), Xultophy and Soliqua for adults with type 2 diabetes, and Wegovy (semaglutide) and Saxenda (liraglutide) for chronic weight management in adults and adolescents who are obese or overweight
Peptides have been quietly rewriting the rules of age management, fat loss, and performance enhancement for the past decade
Not approved for human use
In 2021, the FDA gave the green light to Wegovy to help people with obesity or overweight lose weight
They have replaced the old Low Fat dogma with a new Pro-Meat dogma
The rate of weight loss using Semaglutide will vary from person to person based on their starting weight, genetics, and how seriously they pursue a healthy lifestyle